Vir Biotechnology Names Jason O’Byrne CFO
Vir Biotechnology appoints Jason O’Byrne as CFO, effective October 2, 2024, boosting financial strategy and leadership.
- Latest
- Trending
Vir Biotechnology appoints Jason O’Byrne as CFO, effective October 2, 2024, boosting financial strategy and leadership.
Discover Piper Sandler's eight high-quality defensive biotech stocks poised to thrive in volatile markets.
AbCellera Biologics Inc. progresses with their TCE platform and strategic partnerships, aiming for CTA submissions in Q2 2025.
AbbVie sets quarterly dividend at $1.55 per share, showcasing financial health and strategic growth. Recent acquisitions bolster positive outlook.
"Day One Biopharmaceuticals enhances pipeline, acquiring global rights to promising PTK7-targeting cancer drug DAY301, begins trial soon."
Consider investing in AbbVie and e.l.f., two names with significant growth potential in 2024. AbbVie shines as a quality business ...
NextCure, Inc. (NXTC) is a biopharmaceutical company focused on novel immunomedicines. Strong financials, positive outlook, and promising pipeline.
ActivMAb's new "Antigen Virus" application complements drug discovery strategies for complex protein targets, according to Vaccinex CEO. Ongoing partnerships can ...
GSK's acquisition of Aiolos Bio expands respiratory treatment options, introducing AIO-001, a promising new treatment for asthma patients.
Johnson & Johnson's $2 billion acquisition of Ambrx Biopharma emphasizes its focus on oncology and targeted cancer treatments. #PharmaNews
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.